Home
Loading

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

Get in touch

  • Contact

  • Request a demo

  • Request data updates

  • Add a company

Research

  • Companies

  • Investors

  • People

aVenture

  • Sitemap

  • Feature requests

Member

Backed by

© aVenture Investment Company, 2026. All rights reserved.

San Francisco, CA, USA

Privacy Policy

aVenture Investment Company ("aVenture") is an independent research platform providing detailed analysis and data on startups, venture capital investments, and key industry individuals. It is not a registered investment adviser, broker-dealer, or investment advisor and does not provide investment advice or recommendations. The data provided by aVenture does not constitute recommendations or advice, whether by methodology, analysis, AI-generated content, or a statement written by a staff member of aVenture.

aVenture is not affiliated with any of the people, companies, organizations, government agencies, regulatory bodies, or investment funds we provide coverage for on this site unless explicitly stated otherwise. Users assume full responsibility for decisions made based on information obtained from this platform. Links to external websites do not imply endorsement or affiliation with aVenture. Any links that provide the ability to invest in a primary or secondary transaction in a company are for convenience only and do not constitute solicitations or offers to buy or sell an investment. Investors should exercise heightened precaution and due diligence when investing in private companies, especially those not independently audited.

While we strive to provide valuable insights with objectivity and professional diligence, we cannot guarantee the accuracy of the information provided on our platform. Before making any investment decisions, you should verify the accuracy of all pertinent details for your decision. To the fullest extent permitted by law, aVenture shall not be liable for any direct, indirect, incidental, consequential, or financial damages arising from use of this site, whether by consumers of its contents directly or by persons or organizations covered by our research, even if we are advised of the possibility. Our best-efforts processes and correction request forms do not create a warranty or duty of care.

Profiles on this platform may include content generated in part by large language models (LLMs, artificial intelligence) that aggregate publicly available sources (e.g., SEC EDGAR, public filings, press releases). Source attribution is provided where known; always verify statements and claims here against original sources before relying on any data. Content on our site may contain inaccuracies, omissions, or what are commonly called 'hallucinations' if generated in part or in full by AI / LLMs. The risk can also exist even when content is written by a human, as internal and third-party sources may also have inaccuracies for the same or different reasons. While we randomly audit a proportion of content, this is not exhaustive.

We recommend that an independent auditor be hired to verify the accuracy of the information before relying on it for any sensitive decisions. By accessing this platform, you agree not to rely solely on any information generated by AI, aggregated, or sourced or written otherwise on this site, for investment, financial, or other decisions. aVenture assumes no responsibility for inaccuracies, omissions, or hallucinations. You must independently verify all data from primary sources. Use of this platform constitutes your waiver of claims for reliance-based damages, including negligent misrepresentation. To report an error, request a correction, or dispute information about a company or individual, contact us via our request data updates form.

Loading homepage
Loading
Loading
Home›
Research›
Investment Firms›
Adjuvant Capital
AddedFeb 15, 2024
UpdatedJun 28, 2026
Adjuvant Capital

Adjuvant Capital

Operating

Adjuvant Capital: A global health-focused life sciences investment firm.

Location
New York City, NY, US
Founded
2012
Firm
Compare
Portfolio
Employees
Website

Adjuvant Capital is a life sciences investment firm specializing in global health. They focus on early to mid-stage companies, primarily investing in Series A and B rounds, with occasional participation in later stages. The firm's geographical scope is global, targeting innovations that address critical health challenges worldwide.

Notable portfolio companies include 54Gene, Antiva Biosciences, and Codagenix. Adjuvant Capital's investment philosophy centers on supporting technologies and solutions that can significantly impact global health outcomes. They likely offer strategic guidance and industry connections to their portfolio companies, leveraging their expertise in the life sciences and global health sectors.

Adjuvant Capital - Portfolio Snapshot

Portfolio activity breakdown across disclosed investments and stages

Total Investments17
Current Portfolio Count9
Total Portfolio Exits1

Top Investment Stages

Series A7 (46.7%)
Series B5 (33.3%)
Convertible Note1 (6.7%)
Series C1 (6.7%)
Series D1 (6.7%)

Stage Mix

Series A 47%Series B 33%Convertible Note 7%Series C 7%Series D 7%

Concentration shown as share of disclosed investments by stage.

Recent Investments

Antiva Biosciences logo

Antiva Biosciences

Codagenix logo

Codagenix

InDevR logo

InDevR

Curevo logo

Curevo

54Gene logo

54Gene

VitriVax logo

VitriVax

Excision BioTherapeutics logo

Excision BioTherapeutics

Frontier Nutrition logo

Frontier Nutrition

ChromaCode logo

ChromaCode

X-Vax Technology logo

X-Vax Technology

Adjuvant Capital - Similar Investment Firms

Advection Growth Capital logo

Advection Growth Capital

advectioncap.com

Avoro Capital Advisors logo

Avoro Capital Advisors

avorocapital.com

Advent Life Sciences logo

Advent Life Sciences

adventls.com

Advent Venture Partners logo

Advent Venture Partners

Casdin Capital logo

Casdin Capital

casdincapital.com

Octagon Capital Advisors logo

Octagon Capital Advisors

Aditum Bio logo

Aditum Bio

aditumbio.com

Andav Capital logo

Andav Capital

andavcapital.com

Advantage Capital logo

Advantage Capital

advantagecap.com

Nucleus Adventure Capital logo

Nucleus Adventure Capital

nucleusavc.com

Adaptive Healthcare logo

Adaptive Healthcare

Advancit Capital logo

Advancit Capital

Augury Capital logo

Augury Capital

Apothecary Capital logo

Apothecary Capital

apothcap.com

Global Health Funds logo

Global Health Funds

Adjuvant Capital - Classification

Also Known As
  • Adjuvant Capital, L.P.
NAICS
  • 520000Finance and Insurance
  • 523000Securities, Commodity Contracts, and Other Financial Investments and Related Activities
  • 523900Other Financial Investment Activities
  • 523990All Other Financial Investment Activities
  • 523999Miscellaneous Financial Investment Activities
SIC
  • 6700Holding And Other Investment Offices
  • 6790Miscellaneous Investing
  • 6799Investors, Not Elsewhere Classified
Show 6 more industry codes
NAICS
  • 525000Funds, Trusts, and Other Financial Vehicles
  • 523910Miscellaneous Intermediation
  • 523940Portfolio Management and Investment Advice
SIC
  • 6000Depository Institutions
  • 6720Investment Offices
  • 6722Management Investment Offices, Open-end